Eitr Biologics, Inc. was awarded an indefinite delivery contract by the Defense Health Agency to develop novel nanotherapeutics for combatting pneumonic plague. The potential value of this single award IDV is $4,390,205.63 over its period of performance through August 2028.
Under this vehicle, Eitr Biologics has received a firm fixed price delivery order worth $750,000 to conduct research from September 2023 through August 2024. The work, to be performed in San Diego, California, involves developing nanotherapeutic approaches that penetrate the outer layers of the Yersinia pestis bacterium and target outer membrane proteins. The goal is to assess potential therapies in vitro and in vivo for treating pneumonic plague.
This delivery order aims to support the Defense Health Agency's efforts to research medical countermeasures against threats such as pneumonic plague. By procuring the development of novel nanotherapeutics that can directly target the bacterium, the agency seeks safer and more effective treatment options for this dangerous disease. Eitr Biologics will leverage its IDV to provide specialized research services and products tailored to the agency's requirements.
Generated 1/5/24, 12:47 AM